Factor XIIa (FXIIa) has been explored as a therapeutic target for thrombosis and immune-mediated disorders due to its role at the interface of coagulation and inflammation. However, poor plasma stability and reversible target engagement have limited earlier approaches, underscoring the need for more durable next-generation inhibitors.